ethyl 3-hydroxy-2-methyl-2-propenoate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 乙烯基酸
• 英文名称: ethyl 3-hydroxy-2-methyl-2-propenoate
• 英文别名: 2-Propenoic acid, 3-hydroxy-2-methyl-, ethyl ester；ethyl (E)-3-hydroxy-2-methylprop-2-enoate
• 化学式: C₆H₁₀O₃
• 分子量: 130.144
• InChiKey: UPWSFLJBKRQKBD-SNAWJCMRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 3-hydroxy-2-methyl-2-propenoate 、 2-amino-5-((4-chlorophenyl)sulfanyl)-1,3,4-thiadiazole 生成 2-(4-Chlorophenyl)sulfanyl-6-methyl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one
  参考文献：
  名称：

  TOKUNAGA, YUKIO;ITO, SIGEHXISA;KODZIMA, JOSIYUKI;MAEHNO, SINITIRO;SAVAI, +

  摘要：

  DOI：
• 作为产物：
  描述：

  甲酸乙酯 、 丙酸乙酯 以50%的产率得到
  参考文献：
  名称：

  SPENGLER, J. P.;SCHUNACK, W., ARCH. PHARM., 1984, 317, N 5, 425-430

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS FOR OCULAR DELIVERY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR ADMINISTRATION OCULAIRE
  申请人：GRAYBUG VISION INC

  公开号：WO2020069353A1

  公开（公告）日：2020-04-02

  The present invention provides new prodrags of Sunitinib, Brinzolamide, and Dorzolamide and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (TOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy.

  本发明提供了新的Sunitinib、Brinzolamide和Dorzolamide的前药，以及用于治疗医学疾病的组合物，例如青光眼、与眼内压增高有关的疾病或异常（TOP）、需要神经保护的疾病、年龄相关性黄斑变性或糖尿病视网膜病变。
• [EN] DRUGS AND COMPOSITIONS FOR OCULAR DELIVERY<br/>[FR] MÉDICAMENTS ET COMPOSITIONS À ADMINISTRER PAR VOIE OCULAIRE
  申请人：GRAYBUG VISION INC

  公开号：WO2019118924A1

  公开（公告）日：2019-06-20

  New prodrugs of therapeutically active compounds, including oligomeric prodrugs of ethacrynic acid, and compositions to treat medical disorders, for example glaucoma, a disorder or abnormality related to an increase in intraocular pressure (IOP), a disorder requiring neuroprotection, age-related macular degeneration, or diabetic retinopathy. Also a method for the controlled administration of timolol to a patient in need thereof, such as a human, comprising administering a prodrug of timolol in a microparticle in vivo, wherein the timolol prodrug containing microparticle exhibits in vitro drug release kinetics in an aqueous solution at a pH between 6-8 at body temperature of a substantially consistent release of at least 60% timolol itself by molar ratio to the prodrug of timolol or an intermediate metabolite thereof over at least 100 days.

  新的治疗活性化合物的前药，包括乙丙酸前药的寡聚体前药，以及用于治疗医学障碍的组合物，例如青光眼，一种与眼内压增高相关的障碍或异常，需要神经保护的障碍，年龄相关性黄斑变性，或糖尿病视网膜病变。还提供了一种用于对需要的患者，如人类，进行季洛尔控制给药的方法，包括在体内给予季洛尔的前药微粒，其中季洛尔前药含有微粒体外药物释放动力学，在体温下在pH为6-8的水溶液中，以季洛尔本身至少60%的摩尔比例稳定释放至少100天的季洛尔前药或其中间代谢物。
• METHODS FOR CONTROLLING SURFACE FUNCTIONALITY OF METAL OXIDE NANOPARTICLES, METAL OXIDE NANOPARTICLES HAVING CONTROLLED FUNCTIONALITY, AND USES THEREOF
  申请人：White Meghann A.

  公开号：US20080299046A1

  公开（公告）日：2008-12-04

  Methods for controlling surface functionality of metal oxide nanoparticles, nanoparticles having controlled surface functionality, and uses thereof are described herein. Methods for controlling the surface functionality of a metal oxide nanoparticle are can include attaching a ligand to a metal oxide nanoparticle, where the ligand can include a functional portion that is capable of forming an irreversible bond with an object at a site that is complementary to the functional portion without reacting with other reactive sites that may be present. Moreover, metal oxide nanoparticles having versatile ligands can include an anchoring portion that binds to the surface of the metal oxide nanoparticle and a functional portion that is capable of forming an irreversible bond with an object at a site that is complementary to the functional portion without reacting with other reactive sites that may be present. Uses thereof can include cancer detection, electronics, cosmetics, cellular delivery carriers, magnetic storage media, drug delivery carriers, nanocomposite formation for improved mechanical properties, and the like.

  金属氧化物纳米颗粒表面功能的控制方法，具有受控表面功能的纳米颗粒，以及它们的用途在此进行描述。控制金属氧化物纳米颗粒表面功能的方法可以包括将配体连接到金属氧化物纳米颗粒上，其中配体可以包括一个功能部分，该功能部分能够与物体上的一个与功能部分互补的位置形成不可逆结合，而不会与可能存在的其他反应位点发生反应。此外，具有多功能配体的金属氧化物纳米颗粒可以包括一个锚定部分，该部分与金属氧化物纳米颗粒的表面结合，以及一个功能部分，该功能部分能够与物体上的一个与功能部分互补的位置形成不可逆结合，而不会与可能存在的其他反应位点发生反应。其用途可以包括癌症检测、电子学、化妆品、细胞递送载体、磁存储介质、药物递送载体、用于改善机械性能的纳米复合材料形成等。
• [EN] DYE COMPOUND, METHOD OF PRODUCING DIPYRROMETHENE METAL COMPLEX COMPOUND, METHOD OF PRODUCING DYE MULTIMER, SUBSTITUTED PYRROLE COMPOUND, COLORED CURABLE COMPOSITION, COLOR FILTER, METHOD OF PRODUCING COLOR FILTER, SOLID-STATE IMAGE SENSOR AND LIQUID<br/>[FR] COMPOSÉ DE COLORANT, PROCÉDÉ DE PRODUCTION D'UN COMPOSÉ À BASE D'UN COMPLEXE MÉTALLIQUE DE DIPYRROMÉTHÈNE, PROCÉDÉ DE PRODUCTION D'UN MULTIMÈRE COLORANT, COMPOSÉ DE PYRROLE SUBSTITUÉ, COMPOSITION COLORÉE DURCISSABLE, FILTRE COULEUR, PROCÉDÉ DE PRODUC
  申请人：FUJIFILM CORP

  公开号：WO2012011391A1

  公开（公告）日：2012-01-26

  The invention provides a dye compound having a partial structure represented by the following formula (5): wherein in formula (5), Dye represents a dye structure; G1 represents NR or an oxygen atom; G2 represents a monovalent substituent group having an -Es' value as a steric parameter of 1.5 or more; p represents an integer from 1 to 8; when p is 2 or greater, the two or more structures represented by p may be the same or different from each other; and R represents a hydrogen atom or a monovalent substituent group.

  该发明提供了一种染料化合物，其具有以下式（5）所表示的部分结构：其中在式（5）中，Dye代表染料结构；G1代表NR或氧原子；G2代表具有-Es'值作为1.5或更高的立体参数的一价取代基团；p代表从1到8的整数；当p大于等于2时，由p表示的两个或更多结构可以相同也可以不同；R代表氢原子或一价取代基团。
• [EN] LIVER-TARGETED PRODRUG COMPOSITIONS AND METHODS OF USING THE SAME<br/>[FR] COMPOSITIONS DE PROMÉDICAMENTS CIBLANT LE FOIE ET LEURS MÉTHODES D'UTILISATION
  申请人：UNIV GEORGETOWN

  公开号：WO2017095924A1

  公开（公告）日：2017-06-08

  Disclosed are compositions and methods of delivering a drug to a liver cell or liver tissue in a subject. In some forms, the composition is a prodrug of a drug where the drug, a hydrophilic linker, and a liver-targeted glycol ligand are conjugated together. The hydrophilic linker contains or is coupled to the drug via a cleavable bond such that the cleavable bond is cleaved and the drug released after delivery into a target cell.

  本文揭示了一种将药物传递到受试者的肝细胞或肝组织的组合物和方法。在某些形式中，该组合物是药物的前药，其中药物、亲水性连接剂和肝靶向的糖基配体被共轭在一起。该亲水性连接剂包含或通过可切割键与药物偶联在一起，以便在传递到靶细胞后切割可切割键并释放药物。